Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Visken. Every FDA application for this active ingredient: 1 branded and 14 generic.
As of Nov 14, 2026, FDA lists 15 applications for Pindolol (sold as Visken), first approved Sep 3, 1982, with 1 new use approved and 0 published complete response letters.
First approved: Sep 3, 1982
Applications: 15
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $1.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Pindolol
Part D
$1.9M
-12%
5,525
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
PINDOLOL 10 MG TABLET: $0.824 per unitGeneric · +3% in a year
PINDOLOL 5 MG TABLET: $0.556 per unitGeneric · +3% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Novartis
Aurobindo Pharma USA
Mylan Pharms Inc
Sun Pharm Industries
Zydus Pharms